Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 116, Issue 11, Pages 3042-3049Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI28746
Keywords
-
Categories
Ask authors/readers for more resources
Cylindromatosis (CYLD) is a deubiquitinating enzyme that is altered in patients with familial cylindromatosis, a condition characterized by numerous benign adnexal tumors. However, the regulatory function of CYLD remains unsettled. Here we show that the development of B cells, T cells, and myeloid cells was unaffected in CYLD-deficient mice, but that the activation of these cells with mediators of innate and adaptive immunity resulted in enhanced NF-kappa B and JNK activity associated with increased TNF receptor-associated factor 2 (TRAF2) and NF-kappa B essential modulator (NEMO) ubiquitination. CYLD-deficient mice were more susceptible to induced colonic inflammation and showed a dramatic increase in the incidence of tumors compared with controls in a colitis-associated cancer model. These results suggest that CYLD limits inflammation and tumorigenesis by regulating ubiquitination in vivo.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available